HIV p24/MF59 Vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Chiron Corporation

Conditions

HIV InfectionsHIV Seronegativity

Phase 1

A Study to Test the Safety of Three Experimental HIV Vaccines

CompletedNCT00000946

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity

End: 2001-03-31Target: 40Updated: 2021-10-29

A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults

CompletedNCT00002204

Chiron CorporationHIV Infections, HIV Seronegativity

Target: 40Updated: 2005-06-24